V
19.31
-0.36 (-1.83%)
| Previous Close | 19.67 |
| Open | 19.44 |
| Volume | 466,127 |
| Avg. Volume (3M) | 1,267,104 |
| Market Cap | 1,529,597,312 |
| Price / Sales | 3.93 |
| Price / Book | 3.00 |
| 52 Weeks Range | |
| Earnings Date | 25 Feb 2025 - 3 Mar 2025 |
| Operating Margin (TTM) | -97,069.76% |
| Diluted EPS (TTM) | -4.32 |
| Quarterly Revenue Growth (YOY) | 19.40% |
| Total Debt/Equity (MRQ) | 3.29% |
| Current Ratio (MRQ) | 18.55 |
| Operating Cash Flow (TTM) | -196.99 M |
| Levered Free Cash Flow (TTM) | -104.01 M |
| Return on Assets (TTM) | -32.14% |
| Return on Equity (TTM) | -51.88% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Viridian Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
1.0
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.0 |
| Average | 1.00 |
|
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.01% |
| % Held by Institutions | 112.35% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 47.00 (RBC Capital, 143.40%) | Buy |
| Median | 36.00 (86.43%) | |
| Low | 27.00 (Wells Fargo, 39.82%) | Hold |
| Average | 36.50 (89.02%) | |
| Total | 3 Buy, 1 Hold | |
| Avg. Price @ Call | 20.35 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wells Fargo | 19 Dec 2024 | 27.00 (39.82%) | Hold | 18.73 |
| HC Wainwright & Co. | 17 Dec 2024 | 34.00 (76.07%) | Buy | 20.82 |
| 16 Dec 2024 | 34.00 (76.07%) | Buy | 21.54 | |
| RBC Capital | 17 Dec 2024 | 47.00 (143.40%) | Buy | 20.82 |
| 05 Dec 2024 | 44.00 (127.86%) | Buy | 19.63 | |
| Needham | 25 Nov 2024 | 38.00 (96.79%) | Buy | 21.03 |
| 13 Nov 2024 | 38.00 (96.79%) | Buy | 22.48 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 16 Dec 2024 | Announcement | Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease |
| 13 Dec 2024 | Announcement | Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024 |
| 04 Dec 2024 | Announcement | Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 12 Nov 2024 | Announcement | Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data |
| 05 Nov 2024 | Announcement | Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |